Genome-wide analysis of long noncoding RNA (lncRNA) expression in colorectal cancer tissues from patients with liver metastasis

Cancer Medicine

Volumn 5, Issue 7, 2016, Pages 1629-1639

  Chen, Dong ^a   Sun, Qiang ^a,b,c   Cheng, Xiaofei ^a   Zhang, Lufei ^a,b,c   Song, Wei ^b,c   Zhou, Dongkai ^a,b,c   Lin, Jianjiang ^a   Wang, Weilin ^a,b,c  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b BEIJING HOSPITAL   (China)

^c KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

Author keywords

colorectal cancer (CRC); long noncoding RNA (lncRNA); NAD (P) H Dehydrogenase, Quinone 2 (NQO2)

Indexed keywords

LONG UNTRANSLATED RNA; MESSENGER RNA;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER TISSUE; CELL ACTIVITY; CELL MEMBRANE; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTROLLED STUDY; DISEASE DURATION; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; GENETIC ANALYSIS; HEMICOLECTOMY; HUMAN; HUMAN TISSUE; LAPAROSCOPIC SURGERY; LIVER METASTASIS; MALE; MICROARRAY ANALYSIS; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR LOCALIZATION; TUMOR VOLUME; UPREGULATION; VERY ELDERLY;

EID: 85006226919     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.738     Document Type: Article

References (43)

1. Siegel, R. L., K. D. Miller, and A. Jemal. 2015. Cancer statistics, 2015. CA Cancer J. Clin. 65:5–29.
2. Siegel, R., C. Desantis, and A. Jemal. 2014. Colorectal cancer statistics, 2014. CA Cancer J. Clin. 64:104–117.
3. Jemal, A., F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA Cancer J. Clin. 61:69–90.
4. McAuliffe, J. C., M. Qadan, and M. I. D'Angelica. 2015. Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. J. Gastrointest. Oncol. 6:699–708.
5. Zhong, Y., J. Xu, Y. Wei, L. Ren, Y. Lai, J. Fan, et al. 2007. Surgical treatment of liver metastasis of colorectal cancer. China J. Hepatobiliary Surg. 13:4.
6. Hess, K. R., G. R. Varadhachary, S. H. Taylor, W. Wei, M. N. Raber, R. Lenzi, et al. 2006. Metastatic patterns in adenocarcinoma. Cancer 106:1624–1633.
7. Weidle, U. H., F. Birzele, and A. Kruger. 2015. Molecular targets and pathways involved in liver metastasis of colorectal cancer. Clin. Exp. Metastasis 32:623–635.
8. Duffy, M. J., A. van Dalen, C. Haglund, L. Hansson, E. Holinski-Feder, R. Klapdor, et al. 2007. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur. J. Cancer 43:1348–1360.
9. Wapinski, O., and H. Y. Chang. 2011. Long noncoding RNAs and human disease. Trends Cell Biol. 21:354–361.
10. Mattick, J. S., R. J. Taft, and G. J. Faulkner. 2010. A global view of genomic information–moving beyond the gene and the master regulator. Trends Genet. 26:21–28.
11. Huarte, M. 2015. The emerging role of lncRNAs in cancer. Nat. Med. 21:1253–1261.
12. Ye, L. C., X. Zhu, J. J. Qiu, J. Xu, and Y. Wei. 2015. Involvement of long non-coding RNA in colorectal cancer: from benchtop to bedside (Review). Oncol. Lett. 9:1039–1045.
13. Xue, Y., G. Ma, D. Gu, L. Zhu, Q. Hua, M. Du, et al. 2015. Genome-wide analysis of long noncoding RNA signature in human colorectal cancer. Gene 556:227–234.
14. Padua Alves, C., A. S. Fonseca, B. R. Muys, deBarros E. L. B. R., M. C. Burger, deSouza J. E., et al. 2013. Brief report: the lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines. Stem Cells 31:2827–2832.
15. Kogo, R., T. Shimamura, K. Mimori, K. Kawahara, S. Imoto, T. Sudo, et al. 2011. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 71:6320–6326.
16. Ji, Q., X. Liu, X. Fu, L. Zhang, H. Sui, L. Zhou, et al. 2013. Resveratrol inhibits invasion and metastasis of colorectal cancer cells via MALAT1 mediated Wnt/beta-catenin signal pathway. PLoS ONE 8:e78700.
17. Ling, H., R. Spizzo, Y. Atlasi, M. Nicoloso, M. Shimizu, R. S. Redis, et al. 2013. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 23:1446–1461.
18. Liu, Q., J. Huang, N. Zhou, Z. Zhang, A. Zhang, Z. Lu, et al. 2013. LncRNA loc285194 is a p53-regulated tumor suppressor. Nucleic Acids Res. 41:4976–4987.
19. Sana, J., S. Hankeova, M. Svoboda, I. Kiss, R. Vyzula, and O. Slaby. 2012. Expression levels of transcribed ultraconserved regions uc.73 and uc.388 are altered in colorectal cancer. Oncology 82:114–118.
20. Ge, X., Y. Chen, X. Liao, D. Liu, F. Li, H. Ruan, et al. 2013. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med. Oncol. 30:588.
21. Qi, P., M. D. Xu, S. J. Ni, D. Huang, P. Wei, C. Tan, et al. 2013. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer. J. Transl. Med. 11:122.
22. Dong, R., D. Jia, P. Xue, X. Cui, K. Li, S. Zheng, et al. 2014. Genome-wide analysis of long noncoding RNA (lncRNA) expression in hepatoblastoma tissues. PLoS ONE 9:e85599.
23. Grossi, V., A. Peserico, T. Tezil, and C. Simone. 2014. p38alpha MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance. World J. Gastroenterol. 20:9744–9758.
24. Yang, S., W. S. Li, F. Dong, H. M. Sun, B. Wu, J. Tan, et al. 2014. KITLG is a novel target of miR-34c that is associated with the inhibition of growth and invasion in colorectal cancer cells. J. Cell Mol. Med. 18:2092–2102.
25. Moran, V. A., R. J. Perera, and A. M. Khalil. 2012. Emerging functional and mechanistic paradigms of mammalian long non-coding RNAs. Nucleic Acids Res. 40:6391–6400.
26. Mercer, T. R., M. E. Dinger, and J. S. Mattick. 2009. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10:155–159.
27. Wang, K. C., and H. Y. Chang. 2011. Molecular mechanisms of long noncoding RNAs. Mol. Cell 43:904–914.
28. Vasiliou, V., D. Ross, and D. W. Nebert. 2006. Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family. Hum. Genomics 2:329–335.
29. Gong, X., L. Kole, K. Iskander, and A. K. Jaiswal. 2007. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53. Cancer Res. 67:5380–5388.
30. Sollner, S., and P. Macheroux. 2009. New roles of flavoproteins in molecular cell biology: an unexpected role for quinone reductases as regulators of proteasomal degradation. FEBS J. 276:4313–4324.
31. Patrick, B. A., X. Gong, and A. K. Jaiswal. 2011. Disruption of NAD(P)H:quinone oxidoreductase 1 gene in mice leads to 20S proteasomal degradation of p63 resulting in thinning of epithelium and chemical-induced skin cancer. Oncogene 30:1098–1107.
32. Hsieh, T. C., C. J. Yang, C. Y. Lin, Y. S. Lee, and J. M. Wu. 2012. Control of stability of cyclin D1 by quinone reductase 2 in CWR22Rv1 prostate cancer cells. Carcinogenesis 33:670–677.
33. Malik, M. A., S. A. Zargar, and B. Mittal. 2012. Role of NQO1 609C>T and NQO2 -3423G>A gene polymorphisms in esophageal cancer risk in Kashmir valley and meta analysis. Mol. Biol. Rep. 39:9095–9104.
34. Lee, J., K. S. Kim, M. H. Lee, Y. S. Kim, M. H. Lee, S. E. Lee, et al. 2013. NAD(P)H: quinone oxidoreductase 1 and NRH:quinone oxidoreductase 2 polymorphisms in papillary thyroid microcarcinoma: correlation with phenotype. Yonsei Med. J. 54:1158–1167.
35. Hsieh, T. C., S. Elangovan, and J. M. Wu. 2010. gamma-Tocotrienol controls proliferation, modulates expression of cell cycle regulatory proteins and up-regulates quinone reductase NQO2 in MCF-7 breast cancer cells. Anticancer Res. 30:2869–2874.
36. Gaikwad, N. W., L. Yang, E. G. Rogan, and E. L. Cavalieri. 2009. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones. Free Radic. Biol. Med. 46:253–262.
37. Hubackova, M., R. Vaclavikova, M. Ehrlichova, M. Mrhalova, R. Kodet, K. Kubackova, et al. 2012. Association of superoxide dismutases and NAD(P)H quinone oxidoreductases with prognosis of patients with breast carcinomas. Int. J. Cancer 130:338–348.
38. Hsieh, T. C. 2009. Antiproliferative effects of resveratrol and the mediating role of resveratrol targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 cells. Anticancer Res. 29:3011–3017.
39. Shen, J., R. J. Barrios, and A. K. Jaiswal. 2010. Inactivation of the quinone oxidoreductases NQO1 and NQO2 strongly elevates the incidence and multiplicity of chemically induced skin tumors. Cancer Res. 70:1006–1014.
40. Hsieh, T. C., D. J. Bennett, Y. S. Lee, E. Wu, and J. M. Wu. 2013. In silico and biochemical analyses identify quinone reductase 2 as a target of piceatannol. Curr. Med. Chem. 20:4195–4202.
41. Iskander, K., R. J. Barrios, and A. K. Jaiswal. 2009. NRH:quinone oxidoreductase 2-deficient mice are highly susceptible to radiation-induced B-cell lymphomas. Clin. Cancer Res. 15:1534–1542.
42. Hsieh, T. C., Z. Wang, C. V. Hamby, and J. M. Wu. 2005. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem. Biophys. Res. Commun. 334:223–230.
43. Yu, K. D., G. H. Di, W. T. Yuan, L. Fan, J. Wu, Z. Hu, et al. 2009. Functional polymorphisms, altered gene expression and genetic association link NRH:quinone oxidoreductase 2 to breast cancer with wild-type p53. Hum. Mol. Genet. 18:2502–2517.